
Opinion|Videos|March 19, 2024
Phase 2 Nivo/Cabo in Non-Clear Cell Renal Cell Carcinoma
Elizabeth Plimack, MD discusses recent results from the phase 2 nivolumab and cabozantinib trial in nccRCC.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































